Teva Pharmaceutical Industries Ltd Given Consensus Recommendation of “Buy” by Brokerages (NASDAQ:TEVA)
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) has earned an average rating of “Buy” from the twenty-four analysts that are presently covering the company, AnalystRatingsNetwork reports. Ten analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $56.38.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) opened at 54.46 on Thursday. Teva Pharmaceutical Industries Ltd has a one year low of $36.26 and a one year high of $55.24. The stock has a 50-day moving average of $52.38 and a 200-day moving average of $48.69. The company has a market cap of $46.329 billion and a price-to-earnings ratio of 33.35.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) last released its earnings data on Thursday, May 1st. The company reported $1.22 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $1.22. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $5.11 million. During the same quarter in the prior year, the company posted $1.12 earnings per share. The company’s quarterly revenue was up 2.0% on a year-over-year basis. On average, analysts predict that Teva Pharmaceutical Industries Ltd will post $4.77 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on TEVA shares. Analysts at Canaccord Genuity initiated coverage on shares of Teva Pharmaceutical Industries Ltd in a research note on Friday, June 27th. They set a “hold” rating and a $55.70 price target on the stock. Separately, analysts at Wells Fargo & Co. initiated coverage on shares of Teva Pharmaceutical Industries Ltd in a research note on Tuesday, June 10th. They set a “market perform” rating on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Teva Pharmaceutical Industries Ltd in a research note on Tuesday, June 10th. They now have a $56.00 price target on the stock, up previously from $55.00.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) is an Israel-based pharmaceutical and drug company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.